Mohammad S. Ali

Preparation, characterization, and antitumor activity of new cisplatin analogs with homopiperazines: crystal structure of [PtII(1-methylhomopiperazine)(methylmalonato)].2H2O.

A series of new platinum(II) and (IV) complexes with homopiperazine have been synthesized and characterized by elemental analysis, infrared, and 195Pt nuclear magnetic resonance spectroscopic techniques. The complexes are of two types: [PtIILX] (where L = homopiperazine (hpip), 1-methylhomopiperazine (mhpip), or 1,4-dimethylhomopiperazine (dmhpip), and X = 1,1-cyclobutanedicarboxylato (CBDCA), or methylmalonato ligand) and [PtIV(L-)trans-(Y)2Cl2] (where Y = hydroxo, acetato, or chloro ligand). Among the complexes synthesized, the crystal structure of [PtII(mhpip)(methylmalonato)].2H2O was determined by the single crystal X-ray diffraction method. The crystallographic parameters were orthorhombic, P2(1)2(1)2(1) (no. 19), a = 7.2014(14), b = 7.3348(15), c = 26.971(5) A, and Z = 4. The structure refinements converged to R1 = 0.0641 and wR2 = 0.1847. In this complex, platinum has a slightly distorted square planar geometry with the two adjacent corners being occupied by two nitrogens of the mhpip ligand, whereas the remaining cis positions are coordinated with two oxygen atoms of the methylmalonato group. The mhpip ligand is in a boat conformation and forms five and six membered chelating rings with platinum. The intricate network of intermolecular hydrogen bonds holds the crystal lattice together. Some of these synthesized cisplatin analogs have good in vitro cytotoxic activity against the cisplatin-sensitive human ovarian A2780 (IC50 = 0.083-17.8 microM) and the isogenic cisplatin-resistant 2780CP (IC50 = 20.1-118.1 microM) cell lines.

Synthesis and characterization of platinum(II) and (IV) complexes containing hexamethyleneimine ligand: crystal structure of [PtII(hexamethyleneimine)2(cyclobutanedicarboxylato)]·H2O

Abstract A series of new platinum(II) and platinum(IV) complexes of the type [PtII(HMI)2X] (where HMI=hexamethyleneimine, X=dichloro, sulfato, 1,1-cyclobutanedicarboxylato [CBDCA], oxalato, methylmalonato, or tatronato) and [PtIV(HMI)2Y2Cl2] (where Y=hydroxo, acetato, or chloro) were synthesized and characterized by infrared (IR) spectroscopy, 13C and 195Pt nuclear magnetic resonance (NMR) spectroscopy and elemental analysis. Among the complexes synthesized, [PtII(hexamethyleneimine)2(1,1-cyclobutanedicarboxylato)]·H2O was examined by single-crystal X-ray diffraction. The slightly distorted square planar coordination environment of the platinum metal includes the amino group of the hexamethyleneimine (HMI) molecule and the oxygen atoms of the carboxylato ligand. The cyclobutanedicarboxylic acid (CBDCA) molecule adopts six-member chelating rings with platinum. Hydrogen bonding plays an important part in holding the crystal lattice together.

cis-1,4-Diaminocyclohexane–Pt(II) and –(IV) adducts with DNA bases and nucleosides

A series of new platinum(II) and platinum(IV) adducts of type [P(II)(cis-1,4-DACH)LCl]NO(3,) where cis-1,4-DACH=cis-1,4-diaminocyclohexane, and L=9-ethylguanine, 1-methylcytosine, adenine, adenosine, cytosine, cytidine, guanine, and [Pt(IV)(cis-1,4-DACH)Ltrans-(X)(2)Cl]NO(3), (where Y=hydroxo or acetato), were synthesized and characterized by elemental analysis, infrared spectroscopy, and 1H and 195Pt nuclear magnetic resonance spectroscopy.

Development of (99m)Tc-N4-NIM for molecular imaging of tumor hypoxia.

The nitro group of 2-nitroimidazole (NIM) enters the tumor cells and is bioreductively activated and fixed in the hypoxia cells. 1,4,8,11-tetraazacyclotetradecane (N4) has shown to be a stable chelator for 99mTc. The present study was aimed to develop 99mTc-cyclam-2-nitroimidazole (99mTc-N4-NIM) for tumor hypoxia imaging. N4-NIM precursor was synthesized by reacting N4-oxalate and 1,3-dibromopropane-NIM, yielded 14% (total synthesis). Cell uptake of 99mTc-N4-NIM and 99mTc-N4 was obtained in 13762 rat mammary tumor cells and mesothelioma cells in 6-well plates. Tissue distribution of 99mTc-N4-NIM was evaluated in breast-tumor-bearing rats at 0.5–4 hrs. Tumor oxygen tension was measured using an oxygen probe. Planar imaging was performed in the tumor-bearing rat and rabbit models. Radiochemical purity of 99mTc-N4-NIM was >96% by HPLC. Cell uptake of 99mTc-N4-NIM was higher than 99mTc-N4 in both cell lines. Biodistribution of 99mTc-N4-NIM showed increased tumor-to-blood and tumor-to-muscle count density ratios as a function of time. Oxygen tension in tumor tissue was 6–10 mmHg compared to 40–50 mmHg in normal muscle tissue. Planar imaging studies confirmed that the tumors could be visualized clearly with 99mTc-N4-NIM in animal models. Efficient synthesis of N4-NIM was achieved. 99mTc-N4-NIM is a novel hypoxic probe and may be useful in evaluating cancer therapy.

Synthesis of 99mTc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer

ObjectiveThis study was to develop a 99mTc-labeled α-methyl tyrosine (AMT) using L,L-ethylenedicysteine (EC) as a chelator and to evaluate its potential in breast tumor imaging in rodents. MethodsEC-AMT was synthesized by reacting EC and 3-bromopropyl AMT (N-BOC, ethyl ester) in ethanol/potassium carbonate solution. EC-AMT was labeled with 99mTc in the presence of tin (II) chloride. Rhenium-EC-AMT (Re-EC-AMT) was synthesized as a reference standard for 99mTc-EC-AMT. To assess the cellular uptake kinetics of 99mTc-EC-AMT, 13 762 rat breast cancer cells were incubated with 99mTc-EC-AMT for 0–2 h. To investigate the transport mechanism, the same cell line was used to conduct the competitive inhibition study using L-tyrosine. Tissue distribution of 99mTc-EC-AMT was determined in normal rats at 0.5–4 h. Planar imaging of breast tumor-bearing rats was performed at 30 and 90 min. The data were compared with those of 18F-2-fluoro-2-deoxy-glucose. Blocking uptake study using unlabeled AMT was conducted to investigate the transport mechanism of 99mTc-EC-AMT in vivo. ResultsStructures of EC-AMT and Re-EC-AMT were confirmed by nuclear magnetic resonance, high performance liquid chromatography and mass spectra. In-vitro cellular uptake of 99mTc-EC-AMT in 13 762 cells was increased as compared with that of 99mTc-EC and could be inhibited by L-tyrosine. Biodistribution in normal rats showed high in-vivo stability of 99mTc-EC-AMT. Planar scintigraphy at 30 and 90 min showed that 99mTc-EC-AMT could clearly visualize tumors. 99mTc-EC-AMT uptake could be significantly blocked by unlabeled AMT in vivo. ConclusionThe results indicate that 99mTc-EC-AMT, a new amino acid transporter-based radiotracer, is suitable for breast tumor imaging.

Homopiperazine platinum(II) complexes containing substituted disulfide groups: crystal structure of [PtII(homopiperazine)(diphenylsulfide)Cl]NO3

Abstract A series of new cationic platinum(II) complexes of the type [Pt(L)(R′R″S)Cl]NO3 (where L=homopiperazine or 1-methylhomopiperazine and R′R″S=dimethylsulfide, diethylsulfide, dipropylsulfide, diisopropylsulfide, dibutylsulfide, diphenylsulfide, dibenzylsulfide, methylphenylsulfide, or methyl p-tolylsulfide) were synthesized and characterized by elemental analysis and infrared, 1H and 195Pt nuclear magnetic resonance spectroscopy. Among the complexes synthesized, [PtII(homopiperazine)(diphenylsulfide)Cl]NO3 was examined by single-crystal X-ray diffraction. The slightly distorted square plane of the platinum complex included the amino groups of the homopiperazine molecule in a cis orientation, the sulfur atom of diphenyl sulfide, and a chloride ion. The homopiperazine molecule adopts a boat conformation and forms five- and six-membered chelating rings with platinum. Hydrogen bonding plays an important part in holding the crystal together.

SYNTHESIS, CHARACTERIZATION, AND REPRESENTATIVE CRYSTAL STRUCTURE OF LIPOPHILIC PLATINUMII (HOMOPIPERAZINE)CARBOXYLATE COMPLEXES

Abstract A series of new lipophilic platinum(II) complexes of the type [Pt(HPIP)L2] and [Pt(HPIP)L] (where HPIP = homopiperazine; L = acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, undecanoate, laureate, tridecanoate, myristate, pentadecanoate, palmitate, or heptadecanoate; and LL = oxalate, or tartronate) were synthesized and characterized by elemental analysis, IR, 13CNMR, and 195Pt NMR. In addition, the crystal structure of a representative complex [PtII(HPIP)(pentadecanoate)2], was determined by X-ray diffraction. The crystals were monoclinic, space group P21/c, with a = 28.212(6)Å, b = 3.661(3)Å, c = 10.218(2)Å, and Z = 4. A total of 3940 reflections were collected, and the structure refined to R1 = 0.0522 and wR2 = 0.1333. The slightly distorted square plane of the platinum included the amino groups of the HPIP molecule in cis positions and oxygens from two monodentate pentadecanoates. The HPIP molecule was in a boat conformation and formed five- and six-member chelating rings with platinum. Together, these molecules formed an intricate network of intermolecular hydrogen bonds that held the crystal lattices together.

Development of tyrosine-based radiotracer 99mTc-N4-Tyrosine for breast cancer imaging.

The purpose of this study was to develop an efficient way to synthesize 99mTc-O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-tyrosine (99mTc-N4-Tyrosine), a novel amino acid-based radiotracer, and evaluate its potential in breast cancer gamma imaging. Precursor N4-Tyrosine was synthesized using a 5-step procedure, and its total synthesis yield was 38%. It was successfully labeled with 99mTc with high radiochemical purity (>95%). Cellular uptake of 99mTc-N4-Tyrosine was much higher than that of 99mTc-N4 and the clinical gold standard 18F-2-deoxy-2-fluoro-glucose (18F-FDG) in rat breast tumor cells in vitro. Tissue uptake and dosimetry estimation in normal rats revealed that 99mTc-N4-Tyrosine could be safely administered to humans. Evaluation in breast tumor-bearing rats showed that although 99mTc-N4-Tyrosine appeared to be inferior to 18F-FDG in distinguishing breast tumor tissue from chemical-induced inflammatory tissue, it had high tumor-to-muscle uptake ratios and could detect breast tumors clearly by planar scintigraphic imaging. 99mTc-N4-Tyrosine could thus be a useful radiotracer for use in breast tumor diagnostic imaging.

Synthesis and Evaluation of Amino Acid-Based Radiotracer 99mTc-N4-AMT for Breast Cancer Imaging

Purpose. This study was to develop an efficient synthesis of 99mTc-O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-α-methyl tyrosine (99mTc-N4-AMT) and evaluate its potential in cancer imaging. Methods. N4-AMT was synthesized by reacting N4-oxalate and 3-bromopropyl AMT (N-BOC, ethyl ester). In vitro cellular uptake kinetics of 99mTc-N4-AMT was assessed in rat mammary tumor cells. Tissue distribution of the radiotracer was determined in normal rats at 0.5–4 h, while planar imaging was performed in mammary tumor-bearing rats at 30–120 min. Results. The total synthesis yield of N4-AMT was 14%. Cellular uptake of 99mTc-N4-AMT was significantly higher than that of 99mTc-N4. Planar imaging revealed that 99mTc-N4-AMT rendered greater tumor/muscle ratios than 99mTc-N4. Conclusions. N4-AMT could be synthesized with a considerably high yield. Our in vitro and in vivo data suggest that 99mTc-N4-AMT, a novel amino acid-based radiotracer, efficiently enters breast cancer cells, effectively distinguishes mammary tumors from normal tissues, and thus holds the promise for breast cancer imaging.

1-Methyl-4-(methylamino)piperidine-platinum(II) adducts with DNA bases

A series of platinum(II) monoadducts and diadducts of the type [PtII(mmap)LCl]NO3 and [PtII(mmap)L2](NO3)2 (where mmap = 1-methyl-4-(methylamino)piperidine and L = adenine, 9-methylguanine, 7-methylguanine, cytosine, or uracil) have been synthesized and characterized by elemental analyses and by 1H, 13C, and 195Pt nuclear magnetic resonance spectroscopy. Two adjacent corners of the platinum plane were occupied by the two amino nitrogens of 1-methyl-4-(methylamino)piperidine and the other two positions were occupied by the chloride and nitrogen atoms of the DNA base in monoadducts and two nitrogen atoms of DNA bases in diadducts.